Search Results - "перспективные направления исследований"

Contributors: The study was carried out with the financial support of Kazan State Medical University, grant from the International research board for young scientists (recipient — K.R. Salakhova, 2022), Работа выполнена при финансовой поддержке Казанского государственного медицинского университета, грант Международного научного совета для молодых ученых (получатель — Салахова К.Р., 2022)

Source: Current Pediatrics; Том 22, № 3 (2023); 231-240 ; Вопросы современной педиатрии; Том 22, № 3 (2023); 231-240 ; 1682-5535 ; 1682-5527

Subject Terms: перспективные направления исследований, familial hypercholesterolemia, diagnostics, low-density lipoproteins, dyslipidemia, advanced research directions, семейная гиперхолестеринемия, диагностика, липопротеиды низкой плотности, дислипидемия

File Description: application/pdf

Relation: https://vsp.spr-journal.ru/jour/article/view/3223/1297; Cardiovascular diseases. In: World Health Organization: Official website. Available online: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1. Accessed on April 12, 2023.; Маль Г.С., Смахтина А.М. Вторичная гиперлипидемия: определение, фенотипы и индуцирующие факторы // Международный журнал сердца и сосудистых заболеваний. — 2021. — Т. 9. — № 32. — С. 43–51. — doi: https://doi.org/10.24412/2311-16232021-32-43-51; Thongtang N, Sukmawan R, Llanes EJB, Lee ZV. Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices. Preventive Medicine Reports. 2022;27:a101819. doi: https://doi.org/10.1016/j.pmedr.2022.101819; Концевая А.В., Баланова Ю.А., Имаева А.Э. и др. Экономический ущерб от гиперхолестеринемии на популяционном уровне в Российской Федерации // Рациональная фармакотерапия в кардиологии. — 2018. — Т. 14. — № 3. — С. 393–401. — doi: https://doi.org/10.20996/1819-6446-2018-14-3-393401; Садыкова Д.И., Лутфуллин И.Я. Первичная артериальная гипертензия и гипертрофия миокарда в детском и подростковом возрасте // Педиатрия. Журнал им. Г.Н. Сперанского. — 2009. — Т. 88. — № 5. — С. 16–21.; Vaduganathan M, Mensah GA, Turco JV, et al. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022;80(25):2361–2371. doi: https://doi.org/10.1016/j.jacc.2022.11.005; Gujral J, Gupta J. Pediatric Dyslipidemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available online: https://www.ncbi.nlm.nih.gov/books/NBK585106. Accessed on July 28, 2022.; McGill HC Jr, McMahan CA, Malcom GT, et al. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol. 1997; 17(1):95–106. doi: https://doi.org/10.1161/01.atv.17.1.95; Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338(23):1650–1656. doi: https://doi.org/10.1056/NEJM199806043382302; Ежов М.В., Бажан С.С., Ершова А. И. и др. Клинические рекомендации по семейной гиперхолестеринемии // Атеросклероз. — 2019. — Т. 15. — № 1. — С. 58–98.; Di Taranto MD, Fortunato G. Genetic heterogeneity of Familial hypercholesterolemia: repercussions for molecular diagnosis. Int J Mol Sci. 2023;24(4):3224. doi: https://doi.org/10.3390/ijms24043224; Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of Familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol. 2020;75(20):2553–2566. doi: https://doi.org/10.1016/j.jacc.2020.03.057; Toft-Nielsen F, Emanuelsson F, Benn M. Familial hypercholesterolemia prevalence among ethnicities-systematic review and meta-analysis. Front Genet. 2022;13:840797. doi: https://doi.org/10.3389/fgene.2022.840797; Mainieri F, Tagi VM, Chiarelli F. Recent advances on Familial Hypercholesterolemia in children and adolescents. Biomedicines. 2022;10(5):1043. doi: https://doi.org/10.3390/biomedicines10051043; Wiegman A, Gidding SS, Watts GF, et al. Familial hyperc holesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36): 2425–2437. doi: https://doi.org/10.1093/eurheartj/ehv157; Чубыкина У.В., Ежов М.В., Рожкова Т.А. и др. Пятилетний период наблюдения за пациентами с гомо- и гетерозиготной семейной гиперхолестеринемией в регистре РЕНЕССАНС // Атеросклероз и дислипидемии. — 2023. — № 1. — С. 5–18. — doi: https://doi.org/10.34687/2219-8202.JAD.2023.01.0001; Леонтьева И.В. Семейная гомозиготная гиперхолестеринемия у детей: стратегия ранней диагностики и лечения // Российский вестник перинатологии и педиатрии. — 2021. — Т. 66. — № 4. — С. 118–128. — doi: https://doi.org/10.21508/10274065-2021-66-4-118-128; Леонтьева И.В. Современная стратегия диагностики и лечения семейной гетерозиготной гиперхолестеринемии у детей // Российский вестник перинатологии и педиатрии. — 2020. — Т. 65. — № 4. — С. 27–40. — doi: https://doi.org/10.21508/1027-40652020-65-4-27-40; Исаева А.С., Исакова Е.А. Генетические причины нарушений липидного обмена // Norwegian Journal of Development of the International Science. — 2018. — № 17-2. — С. 34–39.; Berberich AJ, Hegele RA. A modern approach to dyslipidemia. Endocr Rev. 2022;43(4):611–653. doi: https://doi.org/10.1210/endrev/bnab037; Futema M, Taylor-Beadling A, Williams M, Humphries SE. Genetic testing for familial hypercholesterolemia-past, present, and future. J Lipid Res. 2021;62:100139. doi: https://doi.org/10.1016/j.jlr.2021.100139; Chora JR, Iacocca MA, Tichý L, et al. The clinical genome resource (clingen) familial hypercholesterolemia variant curation expert panel consensus guidelines for LDLR variant classification. Genet Med. 2022;24(2):293–306. doi: https://doi.org/10.1016/j.gim.2021.09.012; Futema M, Ramaswami U, Tichy L, et al. Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis. 2021;319:108–117. doi: https://doi.org/10.1016/j.atherosclerosis.2021.01.008; Abou Khalil Y, Marmontel O, Ferrières J, et al. APOE molecular spectrum in a French cohort with primary dyslipidemia. Int J Mol Sci. 2022;23(10):5792. doi: https://doi.org/10.3390/ijms23105792; Cao YX, Sun D, Liu HH, et al. Improvement of definite diagnosis of familial hypercholesterolemia using an expanding genetic analysis. JACC Asia. 2021;1(1):82–89. doi: https://doi.org/10.1016/j.jacasi.2021.04.001; Loaiza N, Hartgers ML, Reeskamp LF, et al. Taking one step back in familial hypercholesterolemia: STAP1 does not alter plasma LDL (Low-Density Lipoprotein) cholesterol in mice and humans. Arterioscler Thromb Vasc Biol. 2020;40(4):973–985. doi: https://doi.org/10.1161/ATVBAHA.119.313470; Tada H, Kawashiri MA, Nomura A, et al. Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease. J Clin Lipidol. 2018;(6):1436–1444. doi: https://doi.org/10.1016/j.jacl.2018.08.006; Nishikawa R, Furuhashi M, Hori M, et al. A resuscitated case of acute myocardial infarction with both familial hypercholesterolemia phenotype caused by possibly oligogenic variants of the PCSK9 and ABCG5 genes and type I CD36 deficiency. J Atheroscler Thromb. 2022; 29(4):551–557. doi: https://doi.org/10.5551/jat.58909; Paquette M, Fantino M, Bernard S, Baass A. Paternal inheritance predicts earlier cardiovascular event onset in patients with familial hypercholesterolemia. Atherosclerosis. 2021;329:9–13. doi: https://doi.org/10.1016/j.atherosclerosis.2021.06.006; Mourre F, Giorgi R, Gallo A, et al. Maternal inheritance of familial hypercholesterolemia gene mutation predisposes to coronary atherosclerosis as assessed by calcium score in adulthood. Arterioscler Thromb Vasc Biol. 2023;43(2):94–103. doi: https://doi.org/10.1161/ATVBAHA.122.318119; Abdul-Razak S, Rahmat R, Mohd Kasim A, et al. Diagnostic performance of various familial hypercholesterolaemia diagnostic criteria compared to Dutch lipid clinic criteria in an Asian population. BMC Cardiovasc Disord. 2017;17(1):264. doi: https://doi.org/10.1186/s12872-017-0694-z; Al-Rasadi K, Al-Waili K, Al-Sabti HA, et al. Criteria for Diagnosis of Familial Hypercholesterolemia: A Comprehensive Analysis of the Different Guidelines, Appraising their Suitability in the Omani Arab Population. Oman Med J. 2014;29(2):85–91. doi: https://doi.org/10.5001/omj.2014.22; Ежов М.В., Сергиенко И.В., Рожкова Т.А. и др. Российские рекомендации по диагностике и лечению семейной гиперхолестеринемии // Атеросклероз и дислипидемии. — 2016. — № 4. — С. 21–29.; Садыкова Д.И., Галимова Л.Ф., Леонтьева И.В., Сластникова Е.С. Оценка толщины комплекса интима-медиа у детей с семейной гиперхолестеринемией // Российский вестник перинатологии и педиатрии. — 2018. — Т. 63. — № 5. — С. 152–154. — doi: https://doi.org/10.21508/1027-4065-2018-63-5-152-154; Kusters DM, Wiegman A, Kastelein JJ, Hutten BA. Carotid intimamedia thickness in children with familial hypercholesterolemia. Circ Res. 2014;114(2):307–310. doi: https://doi.org/10.1161/CIRCRESAHA.114.301430; Pan J, Liu J, Wang H, et al. Association of carotid atherosclerosis with lipid components in asymptomatic low-income Chinese: a population-based cross-sectional study. Front Neurol. 2020;11: 276. doi: https://doi.org/10.3389/fneur.2020.00276; Gidding SS, Wiegman A, Groselj U, et al. Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations. Eur J Prev Cardiol. 2022;29(18): 2301–2311. doi: https://doi.org/10.1093/eurjpc/zwac200; Schefelker JM, Peterson AL. Screening and management of dyslipidemia in children and adolescents. J Clin Med. 2022; 11(21):6479. doi: https://doi.org/10.3390/jcm11216479; Šuštar U, Mlinarič M, Kovač J, et al. Universal screening is an effective strategy for detecting patients with Familial Hypercholesterolemia. Atherosclerosis. 2022;355:7. doi: https://doi.org/10.1016/j.atherosclerosis.2022.06.021; Alonso R, Perez de Isla L, Muñiz-Grijalvo O, Mata P. Barriers to early diagnosis and treatment of familial hypercholesterolemia: current perspectives on improving patient care. Vasc Health Risk Manag. 2020;16:11–25. doi: https://doi.org/10.2147/VHRM.S192401; Галимова Л.Ф., Садыкова Д.И., Сластникова Е.С., Усова Н.Э. Диагностика семейной гиперхолестеринемии у детей: каскадный скрининг от теории к практике // Кардиоваскулярная терапия и профилактика. — 2020. — Т. 19. — № 3. — С. 191–196. — doi: https://doi.org/10.15829/1728-8800-2020-2348; Groselj U, Kovac J, Sustar U, et al. Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review. Atherosclerosis. 2018;277:383–391. doi: https://doi.org/10.1016/j.atherosclerosis.2018.06.858; Medeiros AM, Bourbon M. Genetic testing in familial hypercholesterolemia: is it for everyone? Curr Atheroscler Rep. 2023;25(4): 127–132. doi: https://doi.org/10.1007/s11883-023-01091-5; Sanin V, Schmieder R, Ates S, et al. Population-based screening in children for early diagnosis and treatment of familial hypercholesterolemia: design of the VRONI study. Eur J Public Health. 2022; 32(3):422–428. doi: https://doi.org/10.1093/eurpub/ckac007; Lazaro P, Perez de Isla L, Watts GF, et al. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. J Clin Lipidol. 2017;11(1):260–271. doi: https://doi.org/10.1016/j.jacl.2017.01.002; Louter L, Defesche J, Roeters van Lennep J. Cascade screening for familial hypercholesterolemia: Practical consequences. Atheroscler Suppl. 2017;30:77–85. doi: https://doi.org/10.1016/j.atherosclerosissup.2017.05.019; Vanhoye X, Bardel C, Rimbert A, et al. A new 165-SNP lowdensity lipoprotein cholesterol polygenic risk score based on next generation sequencing outperforms previously published scores in routine diagnostics of familial hypercholesterolemia. Transl Res. 2022;22:1931. doi: https://doi.org/10.1016/j.trsl.2022.12.002; Lima IR, Tada MT, Oliveira TGM, et al. Polygenic risk score for hypercholesterolemia in a Brazilian familial hypercholesterolemia cohort. Atheroscler Plus. 2022;49:47–55. doi: https://doi.org/10.1016/j.athplu.2022.06.002; Tandirerung FJ. The clinical importance of differentiating monogenic familial hypercholesterolemia from polygenic hypercholesterolemia. Curr Cardiol Rep. 2022;24(11):1669–1677. doi: https://doi.org/10.1007/s11886-022-01783-5; Martin AC, Gidding SS, Wiegman A, et al. Knowns and unknowns in the care of pediatric familial hypercholesterolemia. J Lipid Res. 2017;58(9):1765–1776. doi: https://doi.org/10.1194/jlr.S074039; Lampropoulou M, Chaini M, Rigopoulos R, et al. Association between serum lipid levels in Greek children with dyslipidemia and Mediterranean diet adherence, dietary habits, lifestyle and family socioeconomic factors. Nutrients. 2020;12(6):1–15. doi: https://doi.org/10.3390/nu12061600; Hui L, Kwok ME, Nelson AE, et al. Breastfeeding in infancy and lipid profile in adolescence. Pediatrics. 2019;143(5):1–8. doi: https://doi.org/10.1542/peds.2018-3075; Williams LA, Wilson DP. Nutritional management of pediatric dyslipidemia. In: Endotext [Internet]. South Dartmouth (MA): MDText. com, Inc.; 2000. Available online: https://www.ncbi.nlm.nih.gov/books/NBK395582. Accessed on November 01, 2022.; De Jesus JM. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(Suppl 5):S213–S256. doi: https://doi.org/10.1542/peds.2009-2107C; Fiorentino R, Chiarelli F. Treatment of dyslipidaemia in children. Biomedicines. 2021;9(9):1078. doi: https://doi.org/10.3390/biomedicines9091078; Yu-Poth S, Zhao G, Etherton T, et al. Effects of the National Cholesterol Education Program’s Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr. 1999;69(4):632–646. doi: https://doi.org/10.1093/ajcn/69.4.632; Simell O, Niinikoski H, Rönnemaa T, et al. Cohort Profile: the STRIP Study (Special Turku Coronary Risk Factor Intervention Project), an Infancy-onset Dietary and Life-style Intervention Trial. Int J Epidemiol. 2009;38(3):650–655. doi: https://doi.org/10.1093/ije/dyn072; Manousaki D, Barnett TA, Mathieu ME, et al. Tune out and turn in: the influence of television viewing and sleep on lipid profiles in children. Int J Obes (Lond). 2020;44(5):1173–1184. doi: https://doi.org/10.1038/s41366-020-0527-5; Langslet G, Johansen AK, Bogsrud MP, et al. Thirty percent of children and young adults with familial hypercholesterolemia treated with statins have adherence issues. Am J Prev Cardiol. 2021;6: 100180. doi: https://doi.org/10.1016/j.ajpc.2021.100180; Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2019;11:CD006401. doi: https://doi.org/10.1002/14651858.CD006401.pub5; Tada H, Takamura M, Kawashiri M. Familial Hypercholesterolemia: a narrative review on diagnosis and management strategies for children and adolescents. Vasc Health Risk Manag. 2021;17: 59–67. doi: https://doi.org/10.2147/VHRM.S266249; Anagnostis P, Vaitsi K, Kleitsioti P, et al. Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials. Endocrine. 2020;69(2):249–261. doi: https://doi.org/10.1007/s12020-020-02302-8; Braamskamp M, Langslet G, McCrindle BW, et al. Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: The CHARON study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label). Circulation. 2017;136(4):359–366. doi: https://doi.org/10.1161/CIRCULATIONAHA.116.025158; Mytilinaiou M, Kyrou I, Khan M, et al. Familial Hypercholesterolemia: new horizons for diagnosis and effective management. Front Pharmacol. 2018;9:1–29. doi: https://doi.org/10.3389/fphar.2018.00707; Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, et al. Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience. J Clin Lipidol. 2021;15(4):584–592. doi: https://doi.org/10.1016/j.jacl.2021.04.011; Santos RD, Ruzza A, Hovingh GK, et al. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020;383(14):1317–1327. doi: https://doi.org/10.1056/NEJMoa2019910; Ito MK, Sanros RD. PCSK9 Inhibition with monoclonal antibodies: modern management of hypercholesterolemia. J Clin Pharmacol. 2017;57(1):7–32. doi: https://doi.org/10.1002/jcph.766; Lee CJ, Yoon M, Kang HJ, et al. 2022 Consensus statement on the management of familial hypercholesterolemia in Korea. Korean J Intern Med. 2022;37(5):931–944. doi: https://doi.org/10.3904/kjim.2022.121; Erasmo L, Cefalu AB, Noto D, et al. Efficacy of lomitapide in the treatment of Familial Homozygous hypercholesterolemia: Results of a Real-World Clinical Experience in Italy. Adv Ther. 2017;34(5):1200–1210. doi: https://doi.org/10.1007/s12325017-0531-x; Ben-Omran T, Masana L, Kolovou G, et al. Real-World outcomes with lomitapide use in pediatric patients with homozygous familial hypercholesterolaemia. Adv Ther. 2019;36(7):1786–1811. doi: https://doi.org/10.1007/s12325-019-00985-8; Visser ME, Akdim F, Tribble DL, et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res. 2010;51(5):1057–1062. doi: https://doi.org/10.1194/jlr.M002915; Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711–720. doi: https://doi.org/10.1056/NEJMoa2004215; Hermel M, Lieberman M, Slipczuk L, et al. Monoclonal antibodies, gene silencing and gene editing (CRISPR) therapies for the treatment of hyperlipidemia-the future is here. Pharmaceutics. 2023;15(2):459. doi: https://doi.org/10.3390/pharmaceutics15020459; Roch VZ, Santos R. Past, Present, and future of Familial Hypercholesterolemia management. Methodist Debakey Cardiovasc J. 2021;17(4):28–35. doi: https://doi.org/10.14797/mdcvj.887; Tomlinson B, Patil NG, Fok M, et al. Role of PCSK9 Inhibitors in patients with Familial Hypercholesterolemia. Endocrinol Metab (Seoul). 2021;36(2):279–295. doi: https://doi.org/10.3803/EnM.2021.964; Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020:16;382(16):1520–1530. doi: https://doi.org/10.1056/NEJMoa1913805; Reijman MD, Schweizer A, Peterson ALH, et al. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2022;29(9):1361–1368. doi: https://doi.org/10.1093/eurjpc/zwac025; Ishigaki Y, Kawagishi N, Hasegawa Y, et al. Liver transplantation for homozygous familial hypercholesterolemia. J Atheroscler Thromb. 2019;26(2):121–127. doi: https://doi.org/10.5551/jat.RV17029; Björkegren JLM, Lusis AJ. Atherosclerosis: Recent developments. Cell. 2022;185(10):1630–1645. doi: https://doi.org/10.1016/j.cell.2022.04.004; Berta E, Zsiros N, Bodor M, et al. Clinical aspects of genetic and non-genetic cardiovascular risk factors in familial hypercholesterolemia. Genes. 2022;13(7):1–19. doi: https://doi.org/10.3390/genes13071158; Braamskamp MJ, Kusters DM, Avis HJ, et al. Patients with familial hypercholesterolemia who initiated statin treatment in childhood are at lower risk for CHD then their affected parents. Circulation. 2013;128(Suppl 22):A17837.; Kesavan G. Innovations in CRISPR-Based Therapies. Mol Biotechnol. 2023;65(2):138–145. doi: https://doi.org/10.1007/s12033-021-00411-x; Asmamaw M, Zawdie B. Mechanism and applications of CRISPR/ Cas-9-Mediated Genome Editing. Biologics. 2021;15:353–361. doi: https://doi.org/10.2147/BTT.S326422; Alnouri F, Santos RD. New trends and therapies for familial hypercholesterolemia. J Clin Med. 2022;11(22):6638. doi: https://doi.org/10.3390/jcm11226638; Zhao H, Li Y, He L, et al. In Vivo AAV-CRISPR/Cas9-mediated gene editing ameliorates atherosclerosis in familial hypercholesterolemia. Circulation. 2020;141(1):67–79. doi: https://doi.org/10.1161/CIRCULATIONAHA.119.042476; Močnik M, Marčun Varda N. Lipid biomarkers and atherosclerosisold and new in cardiovascular risk in childhood. Int J Mol Sci. 2023; 24(3):2237. doi: https://doi.org/10.3390/ijms24032237; Fricaudet M, Di-Filippo, Mouli P, et al. Performance assessment of salivary screening in familial hypercholesterolemia in children. Atherosclerosis. 2021;331:E183. doi: https://doi.org/10.1016/j.atherosclerosis.2021.06.558

Availability: https://vsp.spr-journal.ru/jour/article/view/3223
https://doi.org/10.15690/vsp.v22i3.2576

View record from BASE

4

Academic Journal

МЕЖДУНАРОДНАЯ НАУЧНАЯ КОНФЕРЕНЦИЯ «ВОЛНОВАЯ ЭЛЕКТРОНИКА И ИНФОКОММУНИКАЦИОННЫЕ СИСТЕМЫ» (WECONF)

Subject Terms: волновая электроника, встроенные микроэлектронные системы, информационные и телекоммуникационные системы, системы управления, обработка информации, электромеханика, акустоэлектроника, актуальные и перспективные направления исследований, акустооптика, научная конференция

5

Academic Journal

90 ЛЕТ ВОСТОЧНО-ЕВРОПЕЙСКОЙ ЛЕСНОЙ ОПЫТНОЙ СТАНЦИИ: ПРОШЛОЕ, НАСТОЯЩЕЕ, БУДУЩЕЕ

Authors: ПУРЯЕВ А. С., РОДИН С. А., ПРОКАЗИН Н. Е.

Subject Terms: ВОСТОЧНО-ЕВРОПЕЙСКАЯ ЛОС,НАУЧНЫЕ РАЗРАБОТКИ,ОПЫТНО-ПРОИЗВОДСТВЕННЫЕ ОБЪЕКТЫ,ПЕРСПЕКТИВНЫЕ НАПРАВЛЕНИЯ ИССЛЕДОВАНИЙ,EAST-EUROPEAN FES,RESEARCH DEVELOPMENTS,RESEARCH COMMERCIAL SITES,ADVANCED RESEARCH

File Description: text/html

Availability: http://cyberleninka.ru/article/n/90-let-vostochno-evropeyskoy-lesnoy-opytnoy-stantsii-proshloe-nastoyaschee-buduschee
http://cyberleninka.ru/article_covers/16945770.png

View record from BASE

6

Academic Journal

MULTIPURPOSE (WEARPROOF AND ANTIFRICTIONAL) COVERINGS ON PRODUCTS FROM CAST IRON ; МНОГОФУНКЦИОНАЛЬНЫЕ (ИЗНОСОСТОЙКИЕ И АНТИФРИКЦИОННЫЕ) ПОКРЫТИЯ НА ИЗДЕЛИЯХ ИЗ ЧУГУНА

Authors: A. P. Laskovnev, A. I. Garost, A. I. Pokrovsky, А. П. Ласковнев, А. И. Гарост, А. И. Покровский

Source: Litiyo i Metallurgiya (FOUNDRY PRODUCTION AND METALLURGY); № 2 (2015); 89-94 ; Литье и металлургия; № 2 (2015); 89-94 ; 2414-0406 ; 1683-6065 ; undefined

Subject Terms: перспективные направления исследований, complex technologies, surface alloying, iron-carbon alloys, cast irons, casting mold, diffusive metallization, key branches of the industry, perspective directions of researches, комплексные технологии, поверхностное легирование, железоуглеродистые сплавы, чугуны, литейная форма, диффузионная металлизация, базовые отрасли промышленности

File Description: application/pdf

Relation: https://lim.bntu.by/jour/article/view/525/515; Горынин И. В. Инновационные технологии в области конструкционных сталей и их сварки // Автоматическая сварка. 2013. № 10–11. С 48–50.; Крушенко Г. Г., Москвичев В. В., Буров А. Е. Применение нанопорошков химических соединений при производстве металлоизделий // Тяжелое машиностроение. 2006. № 9. С. 22–25.; Гольдштейн Я. Е., Мизин В. Г. Модифицирование и микролегирование чугуна. М.: Металлургия, 1986. 272 с.; Крещановский Н. С., С идоренко М. Ф. Модифицирование стали. М.: Металлургия, 1970. 296 с.; Гарост А. И. Железоуглеродистые сплавы: структурообразование и свойства / А. И. Гарост. Минск: Беларуская навука, 2010. 252 с.; Способ выплавки чугуна и способ выплавки стали: пат. 11641 Респ. Беларусь, МПК(2006) C 21 C 1/00, C 21 C 5/00, F 23 G 5⁄027 / А. И. Гарост; заявитель УО «Бел. гос. технол. ун-т». – № а20050280; заявл. 24.03.2005; опубл. 30.12.2006 // Афіцыйны бюл. / Нац. цэнтр інтэлектуал. уласнасці. 2009. № 1.; Способ выплавки чугуна: пат. 14183 Респ. Беларусь, МПК(2006) C21C1/00, C21C5/00, F23G5⁄027 / А. И. Гарост; заявитель УО «Бел. гос. технол. ун-т». – № а20091272; заявл. 31.08.2009; опубл. 30.04.2011 // Афіцыйны бюл. / Нац. цэнтр інтэлектуал. уласнасці. 2010. № 1.; Harast A. I. Chemical Baling of Oily Cast Iron Turnings and Use of Bales to Substitute Expensive and Scarce Scrapes // International Journal of Materials Science and Applications. 2013. Vol. 2, No. 6, P. 194–203. doi:10.11648/j. ijmsa.20130206.15.; Harast A. I. Modification and Microalloying of Iron Carbon Alloys Using Industrial Polymer Scrapes // Journal of Current Advances in Materals Sciences Research. (CAMSR). 2014. Vol. 1, Issue 3 Dec. P. 66–74. www.vkingpub.com/journal/camsr/© American V-King Scientific Publishing.; Горячая пластическая деформация чугуна: структура, свойства, технологические основы / А. И. Покровский. Минск: Беларуская навука. 2010. 256 с.; Effect of the shape of graphite inclusions on acoustic characteristics of articles from cast and deformed iron / A. I. Pokrovskii, A. S. Chaus, E. B. Kunovskii // Metal Science and Heat Treatment. 2011. Vol. 53. No. 7–8, July–August, 2011. P. 311–317. SpringerScience+Business Media, Ink. 2011.; Влияние горячей пластической деформации на изменения микроструктуры чугуна с шаровидным графитом / А. С. Чаус, Я. Сойка, А. И. Покровcкий // Физика металлов и металловедение. 2013. Т. 114. № 1. С. 94–104.; https://lim.bntu.by/jour/article/view/525; undefined

Availability: https://lim.bntu.by/jour/article/view/525

View record from BASE

7

Academic Journal